Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Boston Scientific Corporation
1,500 participants
Mar 4, 2014
OBSERVATIONAL
Conditions
Summary
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
Eligibility
Inclusion Criteria2
- Meets criteria established in locally applicable Vercise System Direction for Use
- At least 18 years old
Exclusion Criteria2
- Meets any contraindication in the Vercise System locally applicable Directions for Use
- Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
Interventions
Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
Locations(84)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02071134